酪氨酸激酶抑制剂类小分子抗肿瘤药物的研究进展  

Research progress of small-molecule tyrosine kinase inhibitors as antitumor agents

作　　者：张星贤 孙莉琼[1] 戚进[1] ZHANG Xing-xian;SUN Li-qiong;QI Jin(Department of Complex Prescription of Traditional Chinese Medicine,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学中药复方研究室,南京211198

出　　处：《中国新药杂志》2018年第22期2616-2629,共14页Chinese Journal of New Drugs

基　　金：2016年度江苏省高校"青蓝工程"基金资助项目

摘　　要：酪氨酸激酶在肿瘤发生发展过程中扮演着重要的角色,以其为导向的分子靶向药物研发已成为现代抗肿瘤药物发展的主流趋势之一,近年来已取得重大进展。本文总结并综述了近年来30余种已上市的酪氨酸激酶抑制剂类小分子抗肿瘤靶向药物,同时概述了相关类似物结构改造的研究进展和趋势。Many studies have demonstrated that protein tyrosine kinases play an important role in the development of tumors.Thus the molecular targeted drugs based on tyrosine kinases have become one of the important trends for R&D of innovative antitumor drugs,and remarkable achievements have been made in recent years.In this paper,according to a wide range of literature,more than 30marketed small-molecule anticancer drugs targeting tyrosine kinases were reviewed,and the development progress of novel analogues was summarized and discussed.

关 键 词：酪氨酸激酶 抗肿瘤 靶向药物 研究进展 

分 类 号：R914.2[医药卫生—药物化学]